US Pharma MarketingEndpoints 100 survey: Biotech CEOs predict MFN maneuvering and offer a few ideas for the FDA
Endpoints 100 1H 2026 CEO survey: optimism rebounds on hot M&A and IPOs; 64% see MFN delaying ex-US filings as execs demand a stable, faster FDA. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
This time a year ago, biotech execs were in the worst mood we’ve seen in the eight years we’ve been surveying them. IPOs were on the skids, the FDA was in turmoil and the Chinese ...
Source: Endpoints News